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The placebo analgesic effect is pain reduction after treatment with an inert substance 
or procedure, administered with suggestions of pain relief. Previous research has shown that 
placebo treatment produces larger pain reduction in males compared to females. The 
hypothesis that males are more responsive to placebo treatment than females was tested 
experimentally in the first paper of this thesis.  The hypothesis was confirmed and the results 
showed that the sex difference was related to a difference in males’ and females’ stress 
response after placebo treatment. Placebo responses on pain unpleasantness and the P2 
component was found in males, but not in females.   
Pain is a multifaceted phenomenon, consisting of physiological, psychological and 
sociocultural components. Thus, it is important that clinical and experimental investigations 
of pain include psychosocial measures, such as measures of stress, anxiety and fear of pain 
(FOP). One widely used device for measurements of FOP is the Fear of Pain Questionnaire-
III (FPQ-III). A more recent device, derived from the FPQ-III, is the Fear of Pain 
Questionnaire-Short Form (FPQ-SF). The second and third paper investigated sex differences 
in FOP, fit, reliability, validity and sex neutrality of these two models in a Norwegian sample. 
It was predicted that FOP would be higher in females than in males and that this would be 
revealed by sex differences in total FPQ-scores, subscale scores and at item level. 
Furthermore, it was hypothesized that the more recent model, the FPQ-SF, would be preferred 
over the FPQ-III. The second paper uncovered higher fear of severe pain in females than in 
males, probably due to sex differences in psychological processes, such as fear and anxiety, 
and interpretation of FPQ-III Severe Pain items. The third paper showed that neither the FPQ-
III nor the FPQ-SF models had good fit to the Norwegian data, although the FPQ-SF model 




adjustment of the present FOP-instruments. Our findings illustrate the importance of 
developing culture or country specific FOP models. The logic behind this is that the 
understanding and perceptions of pain, as well as the responses to pain, may differ across 
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Henry Beecher, a surgeon serving during World War II, was among the first to document the 
importance of emotional and contextual factors in pain and analgesia (Beecher, 1955). 
Towards the end of the war, many of the military field hospitals ran out of morphine. Beecher 
decided to give the wounded soldiers a saline injection before surgery and observed that the 
soldiers experienced pain relief equal to the analgesic effect of morphine. Beecher 
hypothesized that psychological factors modulated the pain (Czerniak & Davidson, 2012). 
Although Beecher’s work has been criticized due to methodological and ethical issues (Di 
Blasi & Klejinen, 2003; Stark, 2016), many consider it the beginning of the systematic 
investigation of the interplay between physiological and psychological systems in analgesic 
processes, as well as the use of randomized controlled trials. 
Placebo effects are observed when symptoms decrease in a group to which an inert 
treatment has been administered, compared to a group to which no treatment has been given 
(Benedetti, 2008). There are two main approaches to investigating and understanding placebo 
effects: expectancy theory and classical conditioning. According to expectancy theory, 
inactive interventions cause placebo effects because of the recipients’ expectations 
(Voudouris, Peck, & Coleman, 1990). The second approach, the theory of classical 
conditioning, suggests that placebo effects are explained by nonconscious learning or 
conscious expectancies after pairings of conditional and unconditional stimuli (Price, Finniss, 
& Benedetti, 2008). In the medical setting, a syringe or a pill represents the conditioned 
stimulus (CS). The active ingredient in the syringe or pill represents the unconditioned 
stimulus (US). Repeated pairings of the US and the CS lead to a conditioned response (CR). 




produced by the US. These mechanisms have been elegantly illustrated in studies on placebo 
effects in the immune and endocrine systems (Ader & Cohen, 1982; Goebel et al. 2002).  
Expectancy theory holds that conditioning may produce placebo effects, but that it is 
the expectancies that elicit placebo responses. The finding that conditioned placebo responses 
are mediated by expectancies has been demonstrated repeatedly (Montgomery & Kirsch, 
1997). Thus, as expectancies are crucial elements in the formation of placebo responses in 
most situations, expectancy theory and the theory of classical conditioning are not mutually 
exclusive approaches.  
 The power of expectancies in placebo effects is demonstrated through the open versus 
hidden design. For example, Benedetti et al. (2003a) found that the effect of morphine was 
reduced by 50% and the effect of diazepam was completely removed when patients were 
unaware that the drugs were administered, compared to patients who were informed that they 
received morphine or diazepam. Similar findings have been reported for other types of pain 
killers (Amanzio, Pollo, Maggi, & Benedetti, 2001; Colloca, Lanotte, & Benedetti, 2004) and 
treatment for Parkinson’s Disease (Lanotte et al., 2005). Thus, therapeutic benefit is, to a 
great extent, dependent upon patient expectancies, even when pharmacological treatment is 
administered.    
 Several studies have reported sex differences in the placebo analgesic effect 
(Aslaksen, Bystad, Vambheim, & Flaten, 2011; Aslaksen & Flaten, 2008; Bjørkedal & Flaten, 
2011; Butcher & Carmody, 2012; Colloca, Pine, Ernst, Miller, & Grillon, 2016; Flaten, 
Aslaksen, Finset, Simonsen, & Johansen, 2006; Krummenacher, Kossowsky, Schwarz, 
Bugger, Kelley, et al., 2014; Theysohn et al., 2014). The majority of those studies report 




of pain conditions and pain symptoms have also been reported, with higher prevalence in 
females than in males for most types of conditions and symptoms (Fillingim, King, Ribeiro-
Dasilva, Rahim-Williams, & Riley, 2009; Forgays, Rzewnicki, Ober, & Forgays, 1993; 
Rollman, & Lautenbacher, 2001; Yunus, 2002). Moreover, sex differences in experimentally 
induced pain have been demonstrated repeatedly (Garcia, Godoy-Izquierdo, Godoy, Perez, & 
Lopez-Chicheri, 2007; Riley, Robinson, Wise, Myers, & Fillingim, 1998).   
Placebo analgesic responses vary across individuals. Some individuals experience no 
analgesic effect from placebo treatment, while others experience complete pain relief. The 
investigation of individual differences in placebo responding has mostly focused on 
psychosocial and genetic variables and on psychological and personality traits. Fear of pain 
has been found to contribute to individual differences in placebo analgesia. Individuals with 
high fear of pain display reduced placebo analgesia compared to individuals with low fear of 
pain (Lyby, Aslaksen, & Flaten, 2010).   
This thesis contributes to unraveling the relationships between sex and placebo 
responding and between sex and fear of pain. Furthermore, the reliability, validity and sex 
neutrality of two models measuring fear of pain is examined. The first paper in the thesis 
investigates whether males are more responsive to placebo analgesic treatment than females. 
The second and third papers investigate whether there are sex differences in fear of pain and 








Pain is a multifaceted phenomenon, involving multiple neuroanatomical and neurochemical 
systems. The International Association for the Study of Pain has defined pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Merskey & Bogduk, 1994).  
Pain may be classified into nociceptive pain, neuropathic pain and somatoform pain. 
Nociceptive pain arises from tissue damage or potential tissue damage, whereas neuropathic 
pain results from damage to or disease in the somatosensory system (Troels et al., 2011). 
Somatoform pain is characterized by chronic, severe and preoccupying pain that is not fully 
explained medically (Landa, Peterson, & Fallon, 2012). Moreover, pain elicited from the skin 
and deeper tissues is termed somatic pain, while pain elicited from the internal organs is 
termed visceral pain (Fink, 2000). Nociception refers to the neural process whereby painful 
stimuli are encoded and processed. The nociceptors are specialized sensory receptors that 
selectively detect painful stimuli. Nociceptors can be found in body areas sensing painful 
stimuli but are absent in the brain with exception of the meninges. The nociceptors transform 
the noxious stimuli into electrical signals, which are transmitted to the central nervous system 
(CNS). The nociceptors are activated by mechanical, thermal or chemical stimuli, and signals 
tissue damage or potential tissue damage to the brain through Aδ and C fibers (Dubin & 
Patapoutian, 2010). The Aδ fibers are highly myelinated and thus provide rapid signal 
conduction. The C fibers are unmyelinated and provide slow signal conduction. The 
nociceptors can be referred to as the afferent nerve fibers because they transmit signals into 
the dorsal horn of the spinal cord to the second-order neurons. The second-order neurons are 




order neurons transmit the pain signal from the dorsal horn of the spinal cord, through the 
spinothalamic tract to the thalamus, or through the spinoreticular tract to the thalamus via the 
brainstem reticular formation. The spinothalamic and spinoreticular tracts represent the two 
main pathways for transmission of nociceptive information (Steeds, 2009). The spinothalamic 
tract is involved in transmission of nociceptive information about the localization of pain, 
whereas the spinoreticular tract is involved in the emotional aspects of pain (Nógrádi, 2006). 
From the thalamus, third-order neurons relay signals to different cortical and subcortical 
structures. These involve the amygdala, hypothalamus, periaqueductal gray (PAG), basal 
ganglia, insula, cingulate cortex and the cerebral cortex. The primary somatosensory cortex 
(S1) is the part of the cortex first activated by the pain signal. The secondary somatosensory 
cortex (S2), located caudal to the primary somatosensory cortex, is the part of the cortex that 
is activated second. Activation of the S1 and S2 is related to the sensation of pain. That is, the 
location and the intensity of the pain. Activation of the cingulate cortex and the insula is 
related to the affective and motivational aspects of pain, and it is argued that this activation 






Figure 1. The ascending pain pathways [online image]. Retrieved and borrowed with 




2.1.1 Pain modulation 
Pain modulation refers to the physiological facilitation or inhibition of nociceptive 
information (Kirkpatrick et al., 2015). Brain stem modulatory systems are central to the 
facilitation of pain (Gebhart, 2004). Descending pain modulatory neurons in the 




different processes (Ossipov, Dussor, & Porreca, 2010). These systems can provide 
bidirectional control of pain, influenced by higher-order functions such as fear, stress and 
expectations (Price, 2015). The most important structures involved in descending inhibitory 
pain modulation are the PAG and the rostroventromedial medulla (RVM). Opioid cells and 
opioid receptors are found in the pain modulatory circuit. Neurons in the PAG project to the 
medulla and serotonergic cells of the raphe nuclei. Next, the serotonergic neurons project 
downwards to the dorsal horn of the spinal cord and provide inhibition. The PAG receives 
signals from cortical sites and has reciprocal connections with the amygdala, dorsal horn, 
parabrachial nuclei and RVM. Through these connections, the PAG initiates descending and 





Figure 2 The descending pain pathways [online image]. Retrieved and borrowed with 




Cognition and attention influence nociceptive processing (Tracey, 2010). Negative 
expectations can reduce the pain-relieving effect of analgesic medications (Bingel et al., 
2011), whereas positive expectations may boost the placebo the analgesic effect (Colloca, 




consideration when investigating pain and pain processing. Brain imaging studies 
investigating the impact cognition and attention has on pain processing, have later 
documented that several subcortical regions are activated during pain anticipation (Shackman 
et al., 2011; Vogt, 2005). The structures that feed back to influence pain due to cognitive 
involvement are the insula, S1, S2, PAG, anterior cingulate cortex (ACC) and the prefrontal 
cortex (PFC) (Villemure & Bushnell, 2002). Distraction from pain has been found to reduce 
activation in pain-responsive areas such as the S1, S2, thalamus and insula (Tracey & 
Mantyh, 2007), and increase activation of the PFC, ACC and PAG (Wiech, Ploner, & Tracey, 
2008). Pain responses mediated by expectations of pain relief is associated with activation of 
the dorsolateral, orbitofrontal and medial prefrontal cortex (Ploghaus et al., 2006; Rainville & 
Duncan, 2006). These structures selectively activate the PAG and the RVM, which sends 
inhibitory projections to the spine (Goffaux, Redmond, Rainville, & Marchand, 2007). 
Expectations of increased pain blocks this type of analgesia. Thus, endogenous pain 
modulatory systems are central for expectancy-based inhibition and excitation of nociceptive 
signals.   
2.1.2 Emotional modulation of pain 
Emotions influence pain, and pain influence emotions. While positive emotions are 
associated with pain inhibition, negative emotions are associated with pain excitation 
(Rainville, Bao, & Chrètien, 2005). Furthermore, the level of arousal is important in 
emotional pain modulation (Rhudy, Bartley, & Williams, 2010). Rhudy and colleagues (2010) 
showed that positive emotions induced by pictures inhibit pain, while negative emotions 
increase pain. Additionally, the associations between emotions and pain was dependent upon 
arousal levels. It was found that increased arousal was necessary for emotional pain 




Fear and anxiety influence pain perception. However, while anxiety is almost 
exclusively associated with increased pain, fear may elicit either analgesia or hyperalgesia 
(Lumley et al., 2011). Fear may be understood as an alarm reaction towards a present threat, 
often accompanied by a need to fight or flight the encounter, and intense negative emotions 
and sympathetic arousal. Anxiety is a future focused threat or worry, often accompanied by a 
need to withdraw, intense negative emotions, hypervigilance and symptoms of somatic 
tension. Furthermore, there is an important distinction between state and trait anxiety 
(Spielberger, 1966). State anxiety refers to the unpleasant emotional arousal experienced in 
threatening or dangerous situations. Trait anxiety refers to the stable individual tendency to 
respond with anxiety when a situation is anticipated as threatening. Fear-elicited analgesic 
responses may be due to activation of the endogenous opioid system (Rhudy & Meagher, 
2000). Furthermore, repeated exposure to fear-eliciting stimuli may result in anticipatory 
anxiety, and hence hyperalgesic responding. 
Negative emotions may increase pain and enhance activation in the amygdala, ACC 
and anterior insula, structures involved in processing of pain unpleasantness and motivation to 
escape pain. In the presence of pain, negative emotions may increase activation in brain 
structures involved in both affective and pain processing. Contrary to this, positive emotions 
decrease pain and pain related activation in the amygdala (Lumley et al., 2011). Thus, pain is 
a biopsychosocial process that involves both sensory and affective components observable 
through brain imaging.  
The finding that emotions modulate pain has repeatedly been demonstrated in clinical 
and experimental studies (Godinho, Magnin, Perchet & Garcia-Larrea, 2006; Rhudy & 
Meagher, 2001), and in studies on the placebo analgesic effect (Eippert, Finsterbusch, Bingel, 




both from a clinical and scientific point of view. Over the past twenty years, the 
understanding of the placebo effect’s influence on symptoms and disease has changed from a 
nuisance factor to a psychobiological phenomenon capable of improving several different 
types of treatment outcomes.  
2.2 Placebo analgesia 
The placebo analgesic effect occurs when inert treatments administered together with 
information that the treatment will reduce pain, elicit pain relief (Wager et al., 2004). Hence, 
positive expectations of treatment effects may modulate pain. Moreover, verbally induced 
expectations of pain relief can be paired with reduced pain intensity in a conditioning trial, a 
procedure termed conditioning. An accompanying effect of expectancy manipulation and 
reduced pain experience is stronger placebo analgesia (Colloca et al., 2013). Furthermore, it 
has been shown that social observational learning may induce expectations of pain relief, and 
thereby placebo analgesic responses (Colloca & Benedetti, 2009). Thus, the principal 
mechanisms underlying placebo analgesia may be divided into two different models a) 
expectancy theory, and b) conditioning theory. There has been an extended debate about these 
two models throughout the years of placebo research. Today, most researchers agree that, 
rather than being mutually exclusive, these are two compatible models often operating in 
concert (Stewart-Williams & Podd, 2004).  
To ensure that the true effect is identified, clinical trials or experimental investigations 
must include an untreated control group. When the response observed in the placebo arm of 
clinical trials is calculated as the placebo effect, the natural course of the disease, the 
regression to the mean, spontaneous remission and potential effects of parallel interventions 
are discounted (Rutherford & Roose, 2013). Thus, calculation of true placebo effects requires 




2.2.1 The principal mechanisms of placebo analgesia: expectancy and learning 
Expectancy-based placebo analgesic effects occur when an expectation is established 
before an ineffective treatment is administered, followed by reduced pain experience. 
Experimentally, expectations are typically induced by administering pain stimuli in a pretest, 
followed by a phase where an inactive substance, told to be an effective pain reliever, is 
administered. Then, the similar procedure as the pretest is conducted in a posttest. The 
placebo analgesic effect can then be calculated by subtracting the pain scores reported in the 
posttest from the scores reported in the pretest.  
The effect of expectancies may be measured by looking at the correlation between 
ratings of expectations and the placebo analgesic response. A high correlation between these 
two measures shows the contribution of expectancies in the placebo analgesic effect (Price et 
al., 1999). This type of correlation has proven to be robust and replicable (Petrovic et al., 
2005).  
Price and colleagues (1999) administered a placebo cream together with three different 
verbal instructions (strong analgesic cream, weak analgesic cream, control cream). The verbal 
information induced different levels of expectancies, with subsequent different levels of 
placebo analgesia. These findings show that strong expectations produce stronger placebo 
analgesic responses than weak expectations. 
The open versus hidden design represents another elegant method for investigating the 
role expectancies has on the placebo analgesic effect. The open versus hidden design involves 
comparing the effect of analgesic medications administered covertly and openly. Studies 
employing this design shows that analgesic drugs are far less potent when they are 




Maggi, & Benedetti, 2001; Levine & Gordon, 1984; Levine, Gordon, Smith, & Fields, 1981). 
Bingel and colleagues (2011) administered pain stimuli and measured the effect of 
remifentanil first covertly and second, overtly. Then, they informed the participants that the 
remifentanil administration had stopped, although in fact, they were still receiving the 
analgesic medication. Covert remifentanil administration reduced average pain ratings from 
66 to 55. Overt remifentanil reduced average pain to 39. Leading the participants to believe 
that the remifentanil administration had stopped increased average pain ratings to 64. Results 
from functional magnetic resonance (fMRI) scans corresponded to the findings on reported 
pain. These findings illustrate the importance of expectations in pain and analgesic responses.   
The understanding of how learning contributes to placebo effects has mostly been 
investigated with respect to classical conditioning. When an organism is exposed to repeated 
pairings of a US and a CS, conditioning occurs. After sufficient pairings, the CS elicits a 
response similar to the response produced by the UR. This type of response is termed a CR. In 
the clinical setting, drugs are paired with contextual factors, such as the doctor’s white coat or 
the smell at the hospital. After repeated pairing the CS acquire the capacity of eliciting a 
response mimicking the response produced by the US (Wickramasekera, 1980). In the case of 
the placebo effect, the placebo pill, capsule or whatever inert substance is used, represents the 
CS. The placebo effect represents the CR. One way of inducing the placebo analgesic effect 
through classical conditioning is to apply a placebo cream to the skin followed by 
surreptitiously lowering the strength of painful stimuli. In the experimental setting, pain 
stimuli are typically administered first in a pretest. Second, the placebo cream is administered 
together with information that the cream contains active analgesic ingredients. Third, the 
participants unknowingly receive pain stimuli of lower intensity than in the pretest. Lastly, 




level as in the pretest and administered to the participants. The placebo response can then be 
measured in postconditioning trials (Klinger, Soost, Flor, & Worm, 2007). In these types of 
circumstances, a placebo effect may occur even without expectations (Benedetti et al., 1998; 
Benedetti, Amanzio, Baldi, Casadio, & Maggi, 1999).   
Expectations may operate simultaneously with different forms of learning (Price, et 
al., 1999; Dodd, Dean, Vian, & Berk, 2017). Presenting both verbal information about 
treatment effects and conditioning procedures leads to amplification of placebo responses 
compared to the situation when only verbal information or conditioning is presented 
(Amanzio & Benedetti, 1999; Benedetti et al., 2003b; Colloca, Sigaudo, & Benedetti, 2008a; 
Montgomery et al., 1997; Price et al., 1999). Price and colleagues (1999) paired placebo 
treatment with either a large or a small decrease in pain stimuli during the conditioning trials. 
The results showed that the magnitude of the placebo effect was associated with the type of 
conditioning (large versus small decrease in pain stimuli). The strong type of conditioning 
probably increased the participants’ expectations more than the weak type of conditioning 
did. Hence, the largest placebo analgesic response was observed in the group that received the 
largest decrease in pain stimuli during conditioning.  
Several researchers have investigated the relative contributions of expectancy and 
conditioning to the placebo effect. Montgomery and Kirsch (1997) employed a conditioning 
procedure and observed a placebo analgesic response. Then, they continued the conditioning 
trials, but informed one of the groups that the pain stimuli had been reduced during the 
conditioning trials. This information abolished the conditioned placebo analgesic response. 
Thus, the placebo analgesic effect may be due to expectancies, conditioning, or both, but in 
situations where expectations and conditioning mechanisms are in conflict, expectancies tend 




2.2.2 The neuroscience of placebo analgesia  
 Placebo analgesic effects involve multiple brain systems, the autonomic nervous 
system and the endocrine system. The first study to investigate the biological mechanisms of 
the placebo analgesic effect was conducted by Levine, Gordon and Fields (1978). In that 
study, it was reported that the µ-opioid antagonist naloxone increased pain and reduced the 
placebo effect. Thus, suggesting that placebo effects are mediated by the endogenous opioid 
system. The finding that naloxone may reverse, or even abolish, the placebo analgesic effect 
has later been confirmed (Grevert, Albert, & Goldstein, 1983; Levine et al., 1984). Through 
several experiments conducted during the 1990s, Benedetti and coworkers (1996) contributed 
to further elucidation of the relation between naloxone, endogenous opioids and the placebo 
analgesic effect. In addition to replicating previous findings showing that the placebo 
response could be reversed or partly reversed by naloxone, Benedetti (1996) illustrated that 
the cholecystokinin (CCK) antagonist proglumide increased placebo analgesia. CCK has an 
inhibitory effect on exogenous opioid analgesics and endogenous opioid pain inhibition and is 
therefore considered an antagonist of the opioid system. Thus, suggesting that reversal or 
blockade of the CCK system increases the placebo analgesic response, possibly through 
potentiating the endogenous opioid system. fMRI-studies by Eippert et al. (2009a; 2009b) 
have demonstrated that naloxone could reverse both placebo responses measured verbally and 
placebo-induced activity in the CNS at the level of the spinal cord’s dorsal horn. Together, 
these findings illustrate that placebo responses can be mediated by different neurotransmitter 
systems with opposing influence: the pronociceptive CCK system, which has an inhibitory 
effect on placebo responses, and the antinociceptive opioid systems, which have an excitatory 




Evidence suggests that expectations may activate opioid systems and that conditioning 
activates subsystems (Amanzio et al., 1999). The type of subsystem activated is dependent 
upon the type of drug, e.g., use of opioids results in conditioning of opioid receptors. 
Furthermore, placebo responses induced by strong expectancies may be blocked by naloxone. 
The same effects have been found after preconditioning with morphine, a procedure that 
involves repeated administration of morphine before replacing the drug with a placebo 
(Benedetti, 2014). However, placebo responses preconditioned with non-opioid substances 
are insensitive to naloxone. Benedetti and colleagues showed that the CB1 cannabinoid 
receptor antagonist rimonabant had no effect on placebo analgesic responses induced through 
preconditioning with morphine but abolished placebo analgesia preconditioned with the 
NSAID ketorolac (Benedetti, Amanzio, Rosato, & Blanchard, 2011). The finding that the 
CB1 cannabinoid receptors can abolish placebo analgesia when an NSAID has been used as 
the US, suggests involvement of endocannabinoid pathways. However, the knowledge about 
placebo responses mediated by the endocannabinoid system is limited compared to placebo 
responses activated through the opioid systems.  
An important role of the reward circuitry in the placebo effect has also been suggested 
(Scott et al., 2008). This line of research was first implicated in placebo effects on 
Parkinsonian patients, but it was later confirmed that reward mechanisms have an important 
role in placebo analgesia as well (de La Fuente Fernàndez, 2009; Scott et al., 2007). In 
Parkinson’s disease (PD), dopamine release in the dorsal striatum is reported to be the core 
mechanism of the placebo effect. Placebo treatment increases synaptic dopamine levels in a 
similar manner as levodopa, a treatment regularly used to control the motor symptoms 
associated with the disease. Increased dopamine activation in the NAc and VTA is associated 




mediates the placebo analgesic effect, but that dopamine release in the ventral striatum is an 
important determining factor for the placebo analgesic effect to occur. It has been suggested 
that dopamine release in the ventral striatum triggers endogenous opioid release (Scott et al., 
2007). Hence, reward mechanisms may have a potentiating role in expectancy-based placebo 
analgesic effects. These observations support the placebo-reward hypothesis, which states that 
there is a link between placebo effects and reward mechanisms and predicts that the ventral 
striatum should be involved in any type of placebo effect.  
The above-described findings shows that expectations are important mediators of both 
opioid and non-opioid systems and that the strength of expectations is important for 
naloxone’s ability to block placebo analgesia. Furthermore, placebo analgesic effects induced 
through preconditioning with non-opioid drugs are opioid independent and cannot be blocked 
by naloxone but may be blocked by cannabinoid antagonists. Thus, placebo analgesia may be 
induced through different pathways and systems.  
Neuroimaging techniques, such as positron emission tomography (PET), fMRI and 
electroencephalography (EEG), have provided further evidence for the neurobiology of the 
placebo analgesic effect. The main aim of imaging studies on placebo analgesia is to identify 
the neurobiological systems involved in placebo responses. Several studies have shown that 
placebo analgesia is associated with top-down activation through the descending pain 
modulatory pathway (Bingel & Tracey, 2008). Placebo analgesia is associated with altered 
activity in several brain structures involved in pain processing. The structures that most 
consistently show reduced activation during placebo analgesia are the dorsal ACC (dACC), 
thalamus and anterior insula (aINS). The magnitude of the placebo analgesic effect has been 
found to consistently correlate with reduced pain-related activity in these three structures 




after placebo treatment suggests that pain is inhibited at the spinal level under placebo 
analgesia (Eippert et al., 2009b). 
 In addition to reduced activity in the abovementioned regions of the brain, placebo 
analgesic responding is associated with increased activity in the ventromedial prefrontal 
cortex (vmPFC), dorsolateral prefrontal cortex (dlPFC), lateral orbitofrontal cortex (lOFC), 
nucleus accumbens-ventral striatum (NAc-VS), PAG and the RVM (Geuter, Koban & Wager, 
2017; Wager & Atlas, 2015). Activation in the dlPFC is central to the initiation of placebo 
analgesia. The rACC and PAG connectivity correlates with reduced somatosensory pain and 
pain report.  
It has also been demonstrated that placebo treatment is related to activation and 
functional connectivity of the PFC, nucleus accumbens (NAc) and amygdala (Petrovic, Kalso 
& Petersson, 2002). In the experience of pain, placebo treatment increases endogenous opioid 
activity and reduces fMRI-measured activation of the amygdala. If naloxone is administered, 
this effect is abolished, further evidencing that placebo analgesic responses involve activation 
of the endogenous opioid system through top-down control. 
Atlas and Wager (2014) conducted a meta-analysis to map the brain regions that are 
most reliably involved in placebo analgesia. The results highlighted that placebo effects were 
accompanied by reduced activation in the dACC, thalamus, insula, amygdala and striatum. 
The former three are regions associated with pain processing, while the latter two relates to 
emotional and cognitive processing. In addition, expectancies of pain relief were associated 
with increased activity in the prefrontal cortex, the PAG and the rostral ACC (rACC). Thus, 
the most reliable brain regions involved in placebo analgesic processing are regions 




represents a challenge for neuroscientific research on placebo analgesia, as it implies that 
several of the pain-responsive brain regions involved in placebo effects are also engaged in 
cognitive and affective processing of tasks that may be unrelated to pain.  
2.2.3  Placebo analgesia and emotions 
The formation and magnitude of placebo responses are influenced by emotions (Flaten 
et al., 2011). These include, among others, stress, fear and anxiety. Placebo analgesic 
responding is associated with reduced reported stress and reduced physiological responses to 
pain stimulation (Aslaksen et al., 2011; Aslaksen et al., 2008). Fear of pain is negatively 
associated with placebo analgesic responding and positively associated with stress (Lyby et 
al., 2010; Lyby, Aslaksen, & Flaten, 2011). Furthermore, an inverse relation between placebo 
analgesia and anxiety has been suggested (Staats, Staats, & Hekmat, 2001). Thus, negative 
emotions may counteract placebo analgesic responding.  
Experimental studies on the placebo analgesic effect involve infliction of pain. 
Expecting or experiencing pain may induce stress and negative emotions and may be 
measured both physiologically, e.g., as increased blood pressure, pulse, and changed heart 
rate variability, and psychologically, e.g., as increased reported unpleasantness, stress, fear or 
anxiety. Placebo treatments induce expectations of symptom relief and hence reduce negative 
emotions, with a subsequent reduction in pain (Vase, Robinson, Verne, & Price, 2005).  
Emotions may be measured according to their valence and arousal (Lang, Bradley, & 
Cuthbert, 1990). Valence reflects the quality of the emotion (positive or negative), whereas 
arousal reflects the strength of the emotion (emotional intensity). Most studies on the role of 
emotional valence in placebo analgesia suggest that positive and negative emotions have a 




placebo analgesia, whereas negative emotions reduce placebo analgesia (Lyby et al., 2010; 
Lyby et al., 2011). However, the relationship between emotional arousal and analgesia has 
proven to be quite complex. High levels of positive emotions are associated with increased 
levels of pain relief compared to lower levels of positive emotions (Rhudy et al., 2001). 
Moreover, intense stress may induce analgesic responding, as observed in studies on stress-
induced analgesia (SIA) (Rhudy et al., 2000). However, intense stress levels may also amplify 
pain, as seen in studies on stress-induced hyperalgesia (SIH) (Martenson, Cetas, & 
Heinricher, 2009).  
2.2.4 Individual differences in placebo responding 
The placebo response varies between individuals. While some experience complete pain 
relief from placebo treatment, others may experience no effect. Individual differences in 
psychosocial factors and psychological traits account for some of these variations (Colloca et 
al., 2013). Dispositional optimism (Geers, Kosbab, Helfer, Wiland, & Wellman, 2007; Geers, 
Wellman, Fowler, Helfer, & France, 2010), somatic focus (Johnston, Atlas, & Wager, 2012), 
empathy (Hunter, Siess, & Colloca, 2014; Rütgen, Seidel, Riecanský, & Lamm 2015), fear of 
pain (Lyby et al., 2010; Zubieta, Yau, Scott, & Stohler, 2006) and anxiety (Ober et al., 2012) 
represent examples of factors of such relevance. Optimism, somatic focus, empathy and 
concern for others are positively associated with increased placebo analgesic responding, 
whereas anxiety, fear of pain and pain catastrophizing are negatively associated with placebo 
analgesic responding (Corsi & Colloca, 2017). Geers and colleagues (2007) showed that high 
levels of dispositional optimism were associated with an increased placebo effect on sleep 
quality, while low levels of dispositional optimism were associated with an increased nocebo 
effect on sleep quality. Agreeableness and resilience, personality traits associated with 




personality traits for endogenous opioid elicitation after placebo treatment (Peciña et al., 
2015).  
More recently, it has been reported that the placebo effect has a genetic signature. The 
placebome refers to a sample of genome-related molecules (genes, proteins, microRNAs) that 
influence placebo responsiveness (Hall, Loscalzo, & Kaptchuk, 2015). Some have reported 
that genetic variability mediates the underlying mechanisms of the placebo effect through 
influencing endorphin, cannabinoid, dopamine and opioid pathways important for placebo 
responsiveness (Colagiuri, Schenk, Kessler, Dorsey, & Colloca, 2015; Litten et al., 2013). For 
example, genetic variations in the catechol-O-methyltransferase (COMT) genotype are 
capable of regulating dopamine levels in the brain and is related to pain perception and 
feelings of pleasure, and thus also placebo responsiveness (Hall et al., 2012). Hall and 
colleagues reported that in patients diagnosed with irritable bowel syndrome (IBS), Met-allele 
carriers seemed to be more prone to placebo treatments than the Val-Val-allele carriers were. 
Another study showed that postoperative patients with mutations of the COMT gene self-
administered lower levels of morphine than others did (De Gregori et al., 2013). However, a 
later study by Forsberg and colleagues (2018) reported that genetic variability in COMT did 
not influence placebo analgesic responsiveness in a sample of healthy participants.  
Others have suggested potential role of the OPRM1 A118G polymorphism in placebo 
responding (Peciña, Love, Stohler, Goldman, & Zubieta., 2014). The OPRM1 A118G 
polymorphism consists of two variants: OPRM1 G carriers and OPRM1 AA carriers. OPRM1 
G carriers have fewer μ-opioid receptors than the AA carriers (Kroslak et al., 2007). Thus, 
placebo responses are less associated with endogenous opioid release in the G carriers than 




The literature about individual differences in placebo responding remains inconsistent. 
This inconsistency may be explained by small sample sizes in many of the studies where 
individual differences are reported. Additionally, the number of different symptoms 
investigated and the use of a wide variety of different experimental designs, procedures and 
scientific approaches complicate the research on how individual differences are related to 
placebo effects. To better understand the relationship between individual differences and 
placebo effects, Horing and colleagues suggested a list of variables to include in forthcoming 
placebo studies, including goal-seeking, self-efficacy, self-esteem, locus of control, optimism, 
desire for control, restraint, fun, sensation, neuroticism, participant sex, Val158Met 
polymorphism, suggestibility, belief in expectation biases, body consciousness and baseline 
symptom severity (Horing, Weimer, Muth, & Enck, 2014). Defining individual markers for 
responsivity to placebo treatments is important in the work of designing future studies, as well 
as for tailoring and personalizing treatments.   
2.3 Nocebo hyperalgesia 
The nocebo hyperalgesic effect is increased pain elicited by verbal suggestions, conditioning 
and/or social observational learning (Blasini, Corsi, Klinger, & Colloca, 2017). Thus, pain 
can be increased by several types of interventions. Interventions directed at influencing 
expectations, without administration of inert substances, have been important for the 
understanding of placebo analgesia and nocebo hyperalgesia. Lorenz and colleagues 
manipulated subjects’ expectancies towards pain induced by brief infrared laser stimuli 
(Lorenz et al., 2005). They used EEG with source localization and showed that the electrical 
dipole in the S2 attenuated when the participants expected decreased pain and amplified when 
they expected increased pain. The dipole strength reflects the duration of the dipole. When 




received a stimulus of low intensity, the dipole length decreased compared to when they 
believed they received a stimulus of high intensity. Additionally, when the participants 
believed they received a stimulus of low intensity but in fact received a stimulus of high 
intensity, the dipole strength increased compared to when they believed they received a 
stimulus of low intensity. The results further revealed that when the participants expected to 
receive pain stimuli of low intensity but actually received stimuli of high intensity, they 
reported lower levels of pain than when they expected to receive stimuli of high intensity. 
Additionally, when they expected to receive stimuli of high intensity but in fact received 
stimuli of low intensity, they reported higher pain than when they believed they received 
stimuli of low intensity. Although Lorenz et al. did not administer any inert treatment and 
only manipulated expectancies, the findings are important for understanding the opposing 
effects of expectancies on pain perception.   
As with placebo analgesia, expectancy-based nocebo hyperalgesia produces effects 
that are measurable at the physiological level. When nocebo treatment induces anticipatory 
anxiety, the opioid agonist CCK is elicited and this facilitates pain signaling (Frisaldi, 
Piedimonte, & Benedetti, 2015). Nocebo treatment may produce increased pain and 
hyperactivity in the hypothalamic-pituitary-adrenal (HPA) axis, measured by increased levels 
of adrenocorticotropic hormone (ACTH) and cortisol (Benedetti, Amanzio, Vighetti, & 
Asteggiano, 2006). Administration of the anxiolytic benzodiazepine diazepam blocks this 
effect, and this suggests that anxiety plays a specifically important role in nocebo 
hyperalgesic responses. However, administration of proglumide, a CCK receptor antagonist, 
is capable of abolishing nocebo hyperalgesic responding completely, without influencing 
neither ACTH nor cortisol. These findings suggest that CCK mediates nocebo hyperalgesia 




Nocebo hyperalgesia and placebo analgesia are often described as opposite processes 
causing opposite effects on subjective pain perception. The findings that the opioidergic and 
CCKergic systems are activated by verbal suggestions of pain relief and pain increase, 
respectively, illustrates that the opposing treatment expectations is also reflected 
neurophysiologically. Interestingly, studies on anxiety-induced analgesia (AIH) and SIA have 
demonstrated that attentional focus is important for activation of the CCKergic and 
opioidergic systems (Benedetti, Carlino, & Pollo, 2011). Both AIH and SIA involve increased 
levels of anxiety. However, during AIH, the subjects direct their attention towards the pain, 
whereas the attentional focus in SIA is at a contextual stressor. These AIH and SIA responses 
are due to activation of the CCKergic and endogenous opioid systems, respectively.  
During SIA, nociceptive responses are reduced as a consequence of stress and fear 
exposure (Yilmaz et al., 2010). Hypoalgesic effects due to stress exposure are mediated by the 
descending inhibitory pain pathway and activation of several receptor subtypes (Butler & 
Finn, 2009) The descending inhibitory pain pathway includes the cortex, hippocampus, 
amygdala, PAG, hypothalamus, brainstem and the spinal cord. GABA, glycine, vasopressin, 
oxytocin, adenosine, endogenous opioids and endocannabinoids constitute the receptor 
subtypes involved in the inhibition of nociceptive information (Butler et al., 2009). In AIH, 
nociceptive responses are exaggerated due to stress coupled with anxiety, with subsequently 
increased activation of the CCKergic systems (Benedetti et al., 2011; Colloca & Benedetti, 
2007).  
 Generally, the majority of studies investigating differences between the placebo and 
the nocebo effect suggests that nocebo hyperalgesic treatments produce increased activity in 
the pain-responsive regions of the brain and reduced activity in the opioid-sensitive brain 




experienced pain, reduces pain threshold, and increases spinal pain signals measured at the 
ipsilateral dorsal horn of the spinal cord (Geuter & Büchel, 2013). These findings suggest that 
nocebo hyperalgesia induced through verbal suggestions may amplify pain signals before they 
reach cortical levels. Conditioned nocebo hyperalgesic treatments may activate neural 
pathways, as measured by increased activation of the thalamus, amygdala and hippocampus 
(Colloca & Grillon, 2014).  
 To sum up, nocebo hyperalgesic effects can be measured in the CNS at cortical, 
subcortical and spinal levels, and the magnitude of nocebo responses is influenced by the 
strength of expectancies and the intensity of accompanying negative emotions. 
2.4 Sex differences in pain and placebo analgesia 
 Males and females tend to respond differently to pain (Bartley & Fillingim, 2013). 
Higher pain sensitivity, and better pain discrimination is found in females than in males 
(Mogil, 2018). Additionally, females have lower pain threshold and tolerance, and display 
less inhibition of pain compared to males (Garcia et al., 2007; Mogil, 2012). Clinical pain 
conditions are more prevalent in females than in males (Mogil, 2012), and it has been 
suggested that clinical pain is more severe in females relative to males (Barnabe et al., 2012; 
Fillingim, Doleys, Edwards, & Lowery, 2003; Keefe et al., 2000; Tang, Yang, Wang, & Lin, 
2012). Although the effects sizes of these observed sex differences vary, the direction of the 
sex differences are clear (Mogil, 2018).   
 Sex differences are also reported in the placebo analgesic effect (e.g., Aslaksen et al., 
2008; Bjørkedal et al., 2011; Butcher & Carmody, 2012; Krummenacher et al., 2014). In a 
recent review article, we examined whether differences between males’ and females’ 




search strategy resulted in 18 studies, whereof 12 investigated the placebo effect and the 
remaining six the nocebo effect. Eight of the placebo studies showed larger placebo responses 
in males than in females, whereas five of the nocebo studies showed larger nocebo responses 
in females than in males. We also tested whether the method used to induce placebo and 
nocebo responses differed across sex and found that verbally induced placebo effects were 
more often observed in males and that conditioned nocebo responses were more often in 
females. As verbally induced placebo responses are due to activation of the endogenous 
opioid system (Amanzio & Benedetti, 1999), the observation that verbally induced placebo 
effects are more frequent in males than in females (Vambheim & Flaten, 2017) may be 
explained by sex differences in the endogenous opioid system.  
The exact basis for sex differences in pain and placebo analgesia remains unclear, but 
it is evident that biological systems and psychological processes are involved and interacting 
(Mogil, 2018). One possibility is that sex differences in pain and pain inhibition are due to sex 
differences in the ascending and descending pain pathways (Mogil, 2012) and opioid 
responding (Zubieta et al., 2002). Animal studies have shown physiological and anatomical 
sex differences in the endogenous descending pain pathways (Loyd, Morgan, & Murphy, 
2007; Loyd & Murphy, 2006). Placebo analgesia is associated with activation of descending 
pain pathways and endogenous opioid elicitation, whereas nocebo hyperalgesia is associated 
with activation of pronociceptive pathways and elicitation of CCK. Endogenous opioids and 
CCK has a bidirectional relationship with placebo analgesia (Colloca & Benedetti, 2005). As 
endogenous opioids are associated with increased placebo analgesic responding, CCK is 
associated with reduced placebo analgesic responding. Therefore, sex differences in the 
neurochemical mechanisms involved in placebo analgesia may explain sex differences 




whereof both influence elicitation of endogenous opioids and CCK, may cause sex 
differences in placebo analgesic and nocebo hyperalgesic responding. Placebo analgesic 
treatments have been found to produce stronger stress reduction in males than in females, 
with a consecutive reduction in pain unpleasantness (Aslaksen et al., 2011). These findings 
were supported by reduced ERP-responses in males, but not in females, in the placebo 
condition compared to the natural history condition. Stress reduction, which was stronger in 
males than in females, explained 23% of the variance in the placebo analgesic effect.  
Possibly, the sex differences in placebo analgesia is due to sex differences in the 
vasopressin and oxytocin system. Vasopressin is involved in evaluation and regulation of 
social behaviors, and vasopressin influences these behaviors differently in males and females 
(Colloca et al., 2016). Colloca and colleagues (2016) aimed to examine whether vasopressin 
modulates placebo analgesia. The participants were given nasal spray containing oxytocin, 
vasopressin or saline. A control group, were no drug or saline were administered, was also 
included. Expectations of pain relief were induced verbally. The results showed that 
pharmacological manipulation of the vasopressin system increased the placebo effect in 
females, but not in males. In females only, an inverse relationship was found between the 
placebo analgesic effect and a) dispositional anxiety, b) baseline cortisol levels, and c) 
vasopressin related cortisol changes. Thus, suggesting a sexual dimorphism in the relationship 
between placebo analgesia, anxiety levels and cortisol responses.  
Oxytocin influences social behaviors and cognitive and emotional processes 
(Theodoridou, Rowe, Penton-Voak, & Rogers, 2009). Kessner and colleagues (2013) reported 
that oxytocin potentiated the placebo analgesic responses in males. However, only male 




and female participants, but there were no increased placebo effect or sex difference in the 
oxytocin group.  
   Psychological and sociocultural factors, e.g., negative affect, anxiety, fear, gender 
roles and gender role expectations, have been found to influence pain differently in males and 
females (Mogil, 2012; Sandford et al., 2002; Wise, Price, Myers, Heft, & Robinson, 2002). 
These differential influences fit well with the sex differences in placebo analgesic responding 
reported in this thesis and other studies (Bjørkedal et al., 2011; Theysohn et al., 2014; 
Vambheim & Flaten, 2017). The factors that seem to contribute to sex differences in placebo 
analgesia are sex differences in stress and the endogenous opioid system.  
Even though considerable progress has been made towards an understanding of sex 
differences in pain and placebo analgesia, there are several challenges to the investigation and 
understanding of these phenomena. First, a large amount of the existing literature on pain 
consists of male samples (Greenspan et al., 2007). Second, most studies are not designed to 
examine sex differences, or do not report sex differences. Mogil (2018) reported that between 
1969 and 2005 79% of the studies published in the journal PAIN consisted of male samples, 
and that another 5% included both males and females, but did not report on sex differences. 
Third, numerous different theoretical and methodological approaches have been used in 
previous studies. Finally, most studies that have reported sex differences in pain and analgesia 






2.5 Fear of pain  
Fear may be defined as the immediate and present emotional and physiological 
response to one specific threat (Turk & Wilson, 2010). Fear of pain (FOP) may then be 
understood as negative emotional and physiological activation in the presence of actual or 
impending pain. Fear increases pain in some situations and decreases pain in other situations, 
and it has been shown that this depends on the emotional arousal level (Lumley et al., 2011). 
FOP is negatively associated with pain threshold (Hirsh, George, Bialosky, & Robinson, 
2008) and positively associated with pain sensitivity (George & Hirsh, 2009). High FOP is 
related to increased pain unpleasantness and reduced pain inhibition and placebo analgesic 
responding (Lyby et al., 2011). It has also been reported that FOP predicts nocebo 
hyperalgesia and increased stress (Aslaksen & Lyby, 2015) and that FOP is essential to 
behavior and coping strategies in chronic pain patients (McNeil et al., 1998).  
Pain-related fears may reflect negative expectations and worries towards future pain, 
and towards the possible consequences of future pain. This latter type of fear may be better 
understood as anxiety (Vambheim & Øien, 2017). Thibodeau and colleagues (2013) reported 
that pain related anxiety reduced females’ tolerance towards pain, but this effect was not 
found in males (Thibodeau, Welch, Katz, & Asmundon, 2013). Thus, the relation between 
fear and pain and the relation between anxiety and pain are somewhat different. Additionally, 
the associations between fear and pain and between anxiety and pain tend to be sex-specific. 
It is therefore important to dissociate fear from anxiety when FOP-measures are used in 
studies on pain and analgesia. The Fear of Pain Questionnaire-III (FPQ-III; McNeil & 
Rainwater, 1998), The Fear of Pain Questionnaire-Short Form (FPQ-SF; Asmundson et al., 
2008), The Pain Anxiety Symptom Scale (PASS; McCracken, Zayfert, & Gross, 1992) and 




used for assessment of pain related fear and anxiety. Paper II and III of the present thesis 
examined sex differences in FOP and applicability of the Fear of Pain Questionnaire-III and 
the Fear of Pain Questionnaire-Short Form, to uncover whether the models are useful tools to 






The overall objective of this thesis was to investigate the hypothesis that there are sex 
differences in the placebo analgesic effect, and explain why males and females tend to 
respond differently to placebo analgesic treatments. In addition, sex differences in FOP was 
examined, and the reliability, validity and sex neutrality of the FPQ-III and the FPQ-SF was 
evaluated. These research questions were addressed: 
a) Are males more responsive to placebo analgesic treatment compared to 
females? 
b) If so, are sex differences in the placebo analgesic effect reflected not only in 
reported pain, but also in physiological parameters like ERP amplitudes?  
c) Can sex differences in placebo analgesia be explained by sex differences in 
emotions? 
d) Are there sex differences in FOP measured by the FPQ-III? 
e) Are the FPQ-III and the FPQ-SF reliable, valid and sex neutral models for 






4.1 The experimental study 
A balanced within-subjects design was used. All participants were tested a total of two times, 
on two different days. One day they participated in the natural history condition, and one day 
the placebo condition. To avoid order effects the order of the conditions was counterbalanced. 
Each condition consisted of three tests: one pretest and two posttests. In total 24 stimuli were 
administered in each test. Measures of pain, stress and arousal were registered during the last 
four pain stimuli. The conditions were identical except for the placebo administration in the 
placebo condition. 
4.1.1 Participants 
 Participants between the age of 19 and 31 years were recruited at the campus of the 
University of Tromsø, The arctic university of Norway. The sample consisted of 54 
undergraduate students (mean age = 23) who volunteered to participate. Participants had to be 
healthy. Medication use, medical history of serious disease, injury, chronic pain or 
cardiovascular disease led to exclusion. Participation was compensated with a 300 NOK gift 
card.     
4.1.2 Experimental pain induction 
 Pain was administered by a contact heat-evoked potential stimulator (CHEPS) (Medoc 
Ltd, Ramat Yishai, Israel). The CHEPS had a thermode surface of 27 mm diameter. 
Thermocouples in the thermofoil continually sent feedback about the skin temperature to the 
CHEPS. The heating rate was 70⁰C/sec and the cooling rate was 40⁰C/sec. The thermofoils 




placed on the participants’ right lower arm and was moved in a predefined pattern after the 
pretest and posttest 1 to avoid sensitization.  
4.1.3 Subjective pain and stress measures 
Pain was measured on a zero to ten numerical rating scale (NRS). The participants 
received 24 stimuli in each test and reported the intensity and unpleasantness of the pain 
verbally to the experimenters (0 = no pain, 10 = most intense pain imaginable, 0 = no pain 
unpleasantness, 10 = unbearable pain unpleasantness). 
 Two adjective pairs from the Short Adjective Check List (SACL) measured the 
participants’ stress. A Norwegian version of the scale was used. The participants were asked 
to rate their stress on a zero to ten scale. The adjective pairs were relaxed-tense and calm-
nervous (0 = completely relaxed / completely calm, 10 = maximally tense / maximally 
nervous). The participants reported their ratings of stress verbally to the experimenters and the 
mean scores of the two adjective pairs were used in the data analysis.  
4.1.4 Event-related potentials (ERPs) 
 ERPs are electrophysiological responses, reflecting cortical activity, to external 
stimuli. In the present study fronto-central and temporal electrodes (Fz, Cz, Pz, C3, C4, T7 
and T8) were used to record contact heat-evoked potentials. Only data from the Cz were 
included in the data analysis. The EEG was recorded continuously with a 0.15 and 100 Hz 
bandpass at a 500 Hz rate. Additionally, to control for ocular artifacts, electrooculography 
(EOG) electrodes were placed above and below the left eye. The time epochs were 1100 
milliseconds and included a 100-millisecond baseline. A TTL-pulse marked CHEPS stimulus 
onset in the EEG-file. Artifacts were controlled and corrected, and data were averaged and 




characteristic segment and timed ERP waveform. ERP components are often represented with 
a peak and are typically sensitive to certain stimuli or experimental manipulations (Kutas & 
Federmeier, 2011). Due to previous findings of a correlation between the second negative 
(N2) and the second positive (P2) ERP components and pain report (Granovsky, Granot, et 
al., 2008) and placebo treatment (Wager, Matre, & Casey, 2006; Watson, El-Deredy, Vogt, & 
Jones, 2006; Colloca et al., 2008b), these two components were analyzed in the present study. 
4.1.5 Placebo manipulation 
 The placebo medication was administered as two capsules containing 75 mg lactose. 
The capsules were administered together with information the following information: These 
capsules contain analgesic ingredients that have a powerful effect on heat pain”. To blind the 
experimenters, four participants received two capsules of 150 mg acetaminophen, with similar 
appearance as the placebo capsules. These four subjects were excluded from the data. The 
experimenters were blinded towards this procedure and did not know whether the participants 
received active or inactive treatment. The placebo effect was computed by subtracting the 
scores on pain intensity, pain unpleasantness, stress, N2 and P2 in the natural history 
condition from the scores in the placebo condition. 
  
4.2 The studies on FOP 
4.2.1 Participants 
 In paper II, 185 healthy participants between 18 and 32 years (mean = 22.5) 
volunteered. The sample consisted of 49.7% females and 50.3% males. Previous or present 




 The sample of paper III consisted of 807 healthy volunteers, whereof 42% were males 
and 58% were females. Participants with previous or present serious injuries, psychological 
and physiological disorders, use of prescription-based and allergy medications were excluded. 
In both papers, all participants spoke Norwegian, due to administration of the Norwegian 
version of the questionnaires and that Norwegian language was used for instructions, 
obtaining consent, and measures of FOP. 
4.2.2 The Fear of Pain Questionnaire-III and The fear of Pain Questionnaire-
Short Form 
The FPQ-III is a 30-item questionnaire where each item is rated 5-point Likert scale, designed 
to examine FOP in both clinical and nonclinical samples. Responders rate their fear of certain 
types of pain on a 1 to 5 scale, where 1 represents no fear and 5 extreme fear. The items are 
thought to measure the three broader dimensions Severe, Medical and Minor FOP. For this 
reason, the FPQ-III is categorized into three subscales, each of which consists of 10 items. 
The subscales measure fear of severe, minor and medical pain. 
 The FPQ-SF is similar to the FPQ-III, except that this scale is reduced to 20-items and 
expanded to 4 subscales. The FPQ-SF’s four subscales are fear of severe, minor, injection, 





Table 1 Fear of Pain Questionnaire III 
1. Being in an automobile accident.Severe 
2. Biting your tongue while eating. Minor 
3. Breaking your arm. Severe 
4. Cutting your tongue licking an envelope. Minor 
5. Having a heavy object hit you in the head. Severe 
6. Breaking your leg. Severe 
7. Hitting a sensitive bone in your elbow – your “funny bone”. Minor 
8. Having a blood sample drawn with a hypodermic needle. Medical 
9. Having someone slam a heavy car door on your hand. Severe 
10.  Falling down a flight of concrete stairs. Severe 
11.  Receiving an injection in your arm. Medical 
12.  Burning your fingers with a match. Minor 
13.  Breaking your neck. Severe 
14.  Receiving an injection in your hip/buttock. Medical 
15.  Having a deep splinter in the sole of your foot probed and removed with tweezers. Medical 
16.   Having an eye doctor remove a foreign particle stuck in your eye. Medical 
17.  Receiving an injection in your mouth. Medical 
18.  Being burned on your face by a lit cigarette. Severe 
19.  Getting a paper-cut on your finger. Minor 
20.  Receiving stitches in your lip. Medical 
21.  Having a foot doctor remove a wart from your foot with a sharp instrument. Medical 
22.  Cutting yourself while shaving with a sharp razor. Minor 
23.  Gulping a hot drink before it has cooled. Minor 
24.  Getting strong soap in both eyes while bathing or showering. Minor 
25.  Having a terminal illness that causes you daily pain. Severe 
26.  Having a tooth pulled. Medical 
27.  Vomiting repeatedly because of food poisoning. Severe 
28.  Having sand or dust blow into your eyes. Minor 
29.  Having one of your teeth drilled. Medical 






5 Summary of Papers  
5.1 Paper I 
Aslaksen, P.M., Bystad, M., Vambheim, S.M. & Flaten, M.A. Gender differences in 
placebo analgesia: event-related potentials and emotional modulation. Psychosomatic 
Medicine, 2011;73(2):193-199. 
 
This study investigated if males are more responsive to placebo analgesic treatment 
than females, and if so, whether this sex difference is accompanied by sex differences in 
physiological and psychological measurements. Due to previous findings of larger placebo 
analgesic effects in males compared to females, larger placebo analgesic responses in reported 
pain and the N2/P2 components in males compared to females were hypothesized. 
Furthermore, a relation between anticipatory stress and placebo responding was assumed.  
Fifty-four healthy subjects were recruited to the experiment, which was conducted 
according to a within-subjects design. Seven subjects were excluded due to poor ERP 
measurements, and ten subjects were excluded because they did not perceive the applied 
stimuli as painful, displayed by < 2 at the NRS in the first round of pain stimulation. 
Significant interactions of Condition x Sex on pain unpleasantness and Condition x Sex in the 
P2 data were found. These interactions showed that placebo treatment reduced pain 
unpleasantness and the P2 ERP components in males, but not in females. A significant main 
effect of Condition on the N2 component showed that the N2 amplitudes were lower in the 
placebo condition than in the natural history condition. However, follow up tests revealed a 
significant interaction of Gender x Test, which showed that the N2 responses were larger in 




females. A significant interaction of sex and stress predicted the placebo response, and the 
larger stress reduction in males than in females explained 23% of the variance in placebo 
responding. Thus, the findings on pain unpleasantness, ERP-measurements and stress were in 
line with the hypothesis. Contrary to the hypothesis, there were no main effects of treatment 
on pain intensity. One potential explanation is that the placebo treatment influenced the 
emotional, but not the sensory-discriminative, component of pain.  
In conclusion, placebo analgesia in males is related to reduced stress. The placebo 
response on the P2 component reflects decreased brain activity, probably in pain sensitive 
regions including the ACC and the insular cortex. A possible explanation is that the placebo 
treatment initiated endorphin release and that the inhibited pain signals reduced cortical 
activity in males. Since at least some placebo analgesic responses are mediated through the 
endogenous opioid system, sex differences in this system may explain the findings from this 
study.      
 
5.2 Paper II  
Vambheim, S.M. & Øien, R.A. Sex Differences in Fear of Pain: Item-Level Analysis 
of the Fear of Pain Questionnaire III. Journal of Pain Research, 2017;10:825-831. 
  
The study examined whether there are sex differences in FOP measured by the FPQ-
III, and whether potential sex differences could be related to specific items at the FPQ-III. It 
was hypothesized that females would score higher than males overall, at the subscales and at 




samples. The questionnaire consists of 30 items and is divided into three subscales: Severe, 
Minor and Medical Pain. 
 In total 185 subjects (92 females) responded to the questionnaire. Sex differences on 
overall, subscales and item-level were investigated. One-way ANOVAs were used to test for 
sex differences in FOP overall and at the level of subscales. Furthermore, ordinal regression 
analysis was conducted to examine sex differences at the item level. Although not reported in 
the published paper, Cohen’s d was used to measure effect size and revealed medium to large 
effect sizes for the sex difference on overall FOP and the Severe Pain subscale. Females 
scored significantly higher than males on overall FOP (p = .001, d = .524) and on the subscale 
Severe Pain (p < .001, d = .726). Additionally, females scored higher than males on 16 of the 
30 FOP items. Among these 16 items, females scored higher than males on all Severe Pain 
items. After controlling for multiple comparisons, females scored higher than males on 6 
items, and among these, 5 items were Severe Pain items. When overall FOP was controlled 
for, 1 item reached significance, also a Severe Pain subscale item (Fall Down Stairs, p <. 001, 
d = .507). Thus, the findings on overall FOP, the Severe Pain subscale, and on the item-level 
were in line with the hypothesis. Contrary to the hypothesis, there were no significant sex 
differences in the Minor or Medical subscale. Although females scored significantly higher 
than males on several items of the Minor and Medical subscale, these differences did not 
contribute to significant sex differences at subscale level.   
 A possible explanation for the findings of this study is that males and females interpret 
the presented items in different ways. This difference in interpretation may be due to sex 
differences in psychosocial mechanisms involving fear and anxiety and emotional reactions to 





5.3 Paper III 
Vambheim, S.M., Lyby, P.S., Aslaksen, P.M., Flaten, M.A., Åsli, O. & Martinussen, 
L.M. The Fear of Pain Questionnaire-III and The Fear of Pain Questionnaire-Short Form: a 
confirmatory factor analysis. Journal of Pain Research, 2017;10:1871-1878. 
  
 Due to previous findings of poor model fit of the FOP-instruments, this study 
examined the FPQ-III and the FPQ-SFs’ model fit, reliability, validity and sex neutrality. It 
was hypothesized that the FPQ-SF model would have better fit and be more sex neutral than 
the FPQ-III model. Furthermore, it was expected that sex differences would be displayed as 
higher FOP-scores in females than in males and poorer fit to the data in the FPQ-III model 
than the FPQ-SF model. 
A total of 807 healthy subjects were enrolled in the study. Approximately 42% of the 
participants were males and 58% were females. Sex differences were examined on the 
subscale level with independent samples t-tests and corrected for multiple comparisons by the 
Holm-Bonferroni procedure. Examination of the model fit and sex neutrality of the FPQ-III 
and the FPQ-SF was performed through confirmatory factor analysis (CFA) by use of AMOS. 
The results disclosed that FOP was higher in females compared to males on all subscales in 
both the FPQ-III and the FPQ-SF. As hypothesized, the FPQ-SF model had better fit and was 
more sex neutral than the FPQ-III model. However, none of the models had good fit 
according to the predefined criteria of good fit. When the models were tested across sex it was 
found that the FPQ-SF was not significantly different for males and females, but the FPQ-III 




In conclusion, even though none of the models proved good fit the FPQ-SF is 






This research project set out to investigate whether there are sex differences in the 
placebo analgesic effect and, if so, to explain why these sex differences appear. Furthermore, 
sex differences in FOP was assessed, and the consistency, validity and sex neutrality of the 
three-factorial model FPQ-III and the four-factorial model FPQ-SF were examined. The 
project provided these main findings: a) placebo analgesic treatment reduced pain 
unpleasantness in males but not in females; b) sex differences in the placebo analgesic effect 
were reflected in the P2 component of ERP-measurements and may be partially explained by 
emotional modulation of anticipatory stress; c) there are sex differences in FOP measured by 
the FPQ-III; d) neither the FPQ-III nor the FPQ-SF are good models for capturing FOP in 
healthy Norwegian samples, but the FPQ-SF is preferable over the FPQ-III.  
 
6.1 Sex differences in placebo analgesia 
Due to repeated findings of larger placebo analgesic responses in males than in 
females in our laboratory (Aslaksen et al., 2008; Bjørkedal et al., 2011; Flaten et al., 2006), 
we wanted to further investigate sex differences in the placebo analgesic effect. In paper I, we 
hypothesized that males would respond with larger placebo analgesic responses compared to 
females. We expected that this difference would be reflected in larger reductions in the N2/P2 
components in males than in females, and assumed that subjective stress would be related to 
the placebo analgesic response. The placebo effect on pain unpleasantness and the P2 
component in male participants, but not in female participants, was due to reduced 
anticipatory stress in males. The interaction of sex and stress predicted the placebo response 
on pain unpleasantness, and stress reduction in males explained 23% of the variance in the 




P2 amplitude in males than in females is in line with Bjørkedal and Flaten (2011) and 
indicates reduced nociceptive signaling to the brain. Hence, the findings of reduced P2 
amplitude in Paper I and Bjørkedal et al. (2011) may be explained by larger activation of the 
endogenous opioid pain modulatory system in males than in females. One possibility is that 
the placebo treatment activated the descending inhibitory pain pathway and mediated pain 
relief through release of endogenous opioids to a larger extent in the male participants than 
the female participants. The endogenous system modulates pain, and sex differences in 
endogenous pain modulation have been reported (Fillingim, 2000). These differences may 
imply that expectations of pain relief modulate anticipatory stress in males, with a subsequent 
altered neurophysiologic reaction to the inflicted pain. Our findings indicate that these 
processes are different in males and females, and may provide an explanation for why males 
are more responsive than females to placebo analgesic treatment. The placebo effects on pain 
and stress in males, but not in females supports previous studies (Aslaksen & Flaten, 2008; 
Flaten et al., 2006). These results suggest that placebo treatment produces larger reductions in 
stress in males than in females and that this has subsequent effects for the production of 
placebo analgesic effects, with larger placebo effects in males than in females.  
In a recent review, we investigated if sex differences in the placebo effect are 
systematic and due to induction method (Vambheim & Flaten, 2017). It should be noted that 
Paper I was one of the included studies in the review. The review found that placebo 
responses are more frequently observed in males than in females. Furthermore, verbally 
induced placebo responses are more often seen in males, and conditioned nocebo responses 
are more often seen in females. We concluded that larger stress reduction in males than in 
females is central to the sex difference in placebo responding. The studies included in the 




performance, IBS and pain. The finding of sex differences in the placebo effect across 
symptoms and responses suggests that sex differences are not specific to pain. A possible 
explanation for sex differences across symptoms and responses may be that males and 
females profit on different types of information. In Paper I, the placebo manipulation was 
induced through verbal information. Placebo effects in males, but not in females, may be due 
to differences in how males and females interpret the information induced in the manipulation 
phase of the experiments. Different types of information processing may have caused larger 
expectations of symptom improvement in males compared to females. The finding that 
placebo treatment produced larger reduction in anticipatory stress in males than in females 
and that the stress reduction significantly influenced the placebo response, could reflect that 
verbal placebo manipulations produces larger placebo effects in males than females due to sex 
differences in information processing. However, as information processing or expectancies 
towards the placebo treatment was not measured, the possibility that the observed sex 
differences were due to information processing or differences in expectancies cannot be ruled 
out.   
The finding of placebo effects on pain unpleasantness, but not pain intensity, may 
suggest that the placebo treatment influenced the affective-emotional dimension of pain 
experience but had no effect on the sensory-discriminative dimension. The medial and the 
lateral pain systems represent two different pain processing networks in the brain, responsible 
for the emotional aspects of pain (pain unpleasantness) and the sensory aspects of pain (pain 
location, duration, intensity), respectively. Thus, the medial pain system represents processing 
of pain from the affective-motivational dimension, whereas the lateral pain system processes 
pain from the sensory-discriminative dimension (Lumley et al., 2011). The medial pain 




N2/P2 components (Garcia-Larrea, Frot, & Valeriani, 2003). Therefore, it is likely that the 
placebo treatment influenced only the affective-motivational dimension of pain in this 
experiment.  
It is recommended that prospective studies tests for sex differences and that the 
constraints on generalizability are listed if this is not possible. Standardizing experimental 
procedures, including both subjective and objective measures of pain responses, and adjusting 
outcome measures for sample sizes will clarify the relative contribution of sex to pain 
responses. Further investigation on the biopsychosocial mechanisms involved in pain related 
sex differences will promote scientific and clinical progress within the field of pain and 
analgesia and may be advantageous for optimizing pain treatment for both males and females. 
 
6.2 FOP 
The FPQ-III is frequently used in clinical and basic research, often as a covariate to 
measurements of pain. FOP is related to an individuals’ pain threshold, pain tolerance 
(George et al., 2009; Hirsh et al., 2008), and also to placebo analgesic responding (Lyby et al., 
2011). Furthermore, these relations are often different for males and females. In 2008, 
Asmundsson, Bovell, Carleton and McWilliams developed the FPQ-SF, a revised version of 
the FPQ-III. They argued that, in addition to increased factor stability, the new model 
displayed sex neutrality. In papers II and III, we examined sex differences in FOP measured 
by the FPQ-III, and the model fit, reliability, validity and sex neutrality of the FPQ-III and the 
FPQ-SF. We hypothesized that FOP-scores would be higher in females than in males and that 
the recently developed FPQ-SF-model would be better suited for measurements of FOP, in 




Deutz, Spijker, & Vlaeyen, 2005) sex differences displayed as larger FOP in females than in 
males were found in both paper II and paper III. The item-level analysis uncovered sex 
differences, expressed as higher FOP in females than in males, on total FOP scores and on the 
Severe Pain subscale. Closer inspection of the items where the largest sex differences were 
found revealed that these items represented situations with potential of serious or fatal 
outcomes. For this reason, we argued that the Severe Pain items may have been interpreted 
differently in males and females, and thus resulted in the observed sex difference in Severe 
Pain. Another possibility is that these items elicited different immediate psychological 
responses in males and females, or that differing interpretations mediated different 
psychological responses in males and females. If so, scoring of Severe FOP items may have 
elicited anxiety in females and fear in males. Replacing the items where the largest sex 
differences are found could help improve the instruments’ applicability across sex. New items 
which describes situations involving moderate to high pain could typically be migraine, 
appendicitis or tooth pain, which represents examples of situations involving moderate to high 
levels of pain that many people have experience with and thus can relate to. 
We found that neither the FPQ-III nor the FPQ-SF is a good model for capturing FOP 
in Norwegian samples. To examine the models’ sex neutrality, we looked at the models 
separately. The fit indices showed that the FPQ-III was a better instrument for measuring FOP 
in males than in females, whereas the FPQ-SF was better for measuring FOP in females than 
in males. When the models sex neutrality was examined by multigroup CFA, the FPQ-SF 
displayed sex neutrality, but the FPQ-III did not. Thus, the FPQ-SF proved to be the best 
model overall and across sex groups. Our findings support previous studies reporting sex 
differences in FOP measured by the FPQ-III (Horn, Alappattu, Gay, & Bishop, 2014; Lyby et 




Sullivan, Thorn, Rodgers, & Ward, 2004) and adds to the literature by showing that the 
present models need to be adjusted when used to explain FOP in Norway. In a recent study 
we developed a new, refined model for measurements of FOP in Norwegian samples 
(Vambheim, Lyby, Aslaksen, Flaten, Åsli, Bjørkedal, et al., 2017). The new model, termed 
the Fear of Pain Questionnaire Norway (FPQ-NOR), consists of 27 items and the 6 
subcategories of minor pain, severe pain, injection pain, fracture pain, dental pain and cut 
pain. Thus, this model is reduced compared to the FPQ-III-model in terms of the number of 
items but is extended to three more subcategories. The extension of subcategories may be 
useful in clinical practice and research, as it facilitates separation of different sorts of FOP.  
 
6.3 Implications and limitations 
Our findings may have implications for further research and clinical practice. Because 
expectations of symptom relief and emotional modulation influence placebo responding, any 
therapeutic context has the potential of eliciting placebo effects. Placebo mechanisms can be 
activated even in situations where no placebo is administered, and these mechanisms can 
interact with active treatments. If the observed sex difference in placebo responding is due to 
a sex difference in the endogenous pain modulatory system, females undergoing pain 
treatment may be predisposed to poorer clinical outcomes than males.  
The findings from the studies on FOP are important in the future work of 
understanding sex differences in FOP, pain and analgesia, as well as for improving 
measurement inventories used in basic and clinical research and in clinical practice. Sex 
differences in FOP, pain, and pain inhibition should be considered in the work of delineating 




medical treatments (Enck, Bingel, Schedlowski, & Rief, 2013). Maximizing placebo effects, 
or placebo related effects, in clinical practice could improve the treatment outcome in clinical 
settings. Although research on how placebo mechanisms can be utilized in clinical practice is 
in its infancy, it is reasonable to suggest that reducing stress, anxiety and FOP, and enhancing 
expectancies towards treatment efficacy, are useful strategies for optimizing treatment 
outcomes in most therapeutic settings.     
The finding of a sex difference on placebo analgesic responding in Paper I has some 
important implications for future experimental designs. We recommend that prospective 
studies are designed so that further clarification of the association between placebo 
responsiveness and sex can be obtained. Future studies should report results separately for 
males and females, and treatment outcomes should be analyzed for sex differences. 
In paper I, we acclaimed that the existing FOP models needed further adjustment. The 
FPQ-NOR, which was identified in a more recent paper, proved good fit in general and across 
sex. However, the young, nonclinical sample included in that paper may limit the 
generalizability of the findings. A priority for future studies will be to examine the models’ 
applicability to other types of samples, e.g., patient and age groups.  
 Expectancies of treatment efficacy were not measured in Paper I. This omission 
represents a limitation of that study, as the sex differences in placebo responding may have 
been due to differing expectations in males and females towards the placebo treatment. The 
relatively low number of participants may limit the generalizability of the findings. 
Additionally, the pain levels were low, reflected in mean pain intensity and pain 




explain the lacking placebo response in the pain intensity data. These challenges could be 
avoided through individual calibration of the pain stimuli.  
 The samples included in paper II and III consisted mainly of undergraduate students. 
Thus, both samples were homogenous by age and education. As FOP has been found to vary 
across age (Albaret, Sastre, Cottencin, & Mullet, 2004) inclusion of different age groups is 
recommended in future studies. A Norwegian version of the FPQ-III was used, and all 
participants responded to the FPQ-III. Translational and linguistic issues can therefore not be 
discounted, and administration of the FPQ-SF may have produced other results. Moreover, 






7 Overall Conclusions 
 The findings from this thesis sheds light on some important aspects of sex differences in 
placebo analgesia and FOP, as well as instruments frequently used to measure FOP. The 
results may have important implications for future clinical investigations on pain, analgesia 
and the role of emotional modulation. The presented findings should be further tested in 
clinical populations and on heterogeneous age groups to ensure generalizability and 
applicability.  
a) There are sex differences in the placebo analgesic effect, with larger placebo 
analgesic responses on pain unpleasantness in males compared to females. 
b) Sex differences in the placebo analgesic effect are accompanied by reduced P2 
amplitude  
c) Sex differences in the placebo analgesic effect are partially explained by sex 
differences in modulation of anticipatory stress. 
d) There are sex differences in FOP measured by the FPQ-III. 
e) Neither the FPQ-III nor the FPQ-SF are good models for measuring FOP in 
Norwegian samples. However, the FPQ-SF showed better fit indices overall and 
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